FIELD: biotechnology.
SUBSTANCE: following is described: a group of inventions including a chimeric protein L1 of papillomavirus as a component of a vaccine against papillomavirus, a virus-like particle of papillomavirus for producing an immunogenic composition, an immunogenic composition for preventing diseases or infections associated with papillomavirus, an isolated polynucleotide encoding the chimeric protein L1 of papillomavirus, a vector used for producing a papillomavirus virus-like particle or a nucleic acid-based immunogenic composition, a baculovirus used to produce a papillomavirus virus-like particle or a nucleic acid-based immunogenic composition, a host cell for producing a chimeric papillomavirus L1 protein and a papillomavirus virus-like particle, and a method of producing a papillomavirus virus-like particle.
EFFECT: invention expands the arsenal of vaccine components against papillomavirus.
23 cl, 25 dwg, 28 tbl, 62 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT IMMUNOGENIC COMPOSITION AGAINST HUMAN PAPILLOMAVIRUS | 2020 |
|
RU2806424C2 |
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| IMPROVED IMMUNOGENICITY OF L2 HPV PEPTIDE | 2017 |
|
RU2743016C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| MULTIMERIZING POLYPEPTIDES DERIVED FROM DOMAIN WITH ROLL-TYPE PENTONE BASE OF ADENOVIRUS | 2019 |
|
RU2820522C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
